TRIAL SUCCESS

Astellas GATHER2 data confirm IZERVAY slowed GA growth, already an approved drug

Astellas says avacincaptad pegol met its GA-growth primary endpoint in GATHER2, replicating the effect that already won IZERVAY approval, without disclosing new effect sizes.

By AppliedXLJuly 9, 2026Trial NCT04435366

Executive Summary

Astellas disclosed that its geographic atrophy drug met the primary endpoint in the trial that originally supported its approval, closing out a readout that had sat unresolved in public tracking for years.
Because the drug is already approved and this result matches the effect behind that approval, the news functions as validation of a settled program rather than a fresh clinical bet.
Astellas is following the confirmation with a set of biomarker, driving-eligibility, and durability analyses at a retina specialty meeting, extending the evidence base without changing the regulatory picture.
The drug remains the only Phase 3 complement C5 inhibitor to have completed testing in this disease, with the nearest same-target programs running in unrelated conditions and a same-mechanism GA rival still enrolling.

What Astellas disclosed

Astellas said IZERVAY met the registered GATHER2 primary endpoint, the mean rate of geographic atrophy growth measured by fundus autofluorescence through Month 12, in a press release tied to presentations planned for the American Society of Retina Specialists meeting running July 15 to 18, 2026. The release did not include a numeric effect size, confidence interval, or p-value for that endpoint. The trial itself, registered as NCT04435366, enrolled 448 patients across the United States and Germany and reached its primary completion in July 2022. Astellas+1

A result already in the label

IZERVAY is currently approved for geographic atrophy in the United States, Australia, and Macau, and conditionally in Japan, and Astellas said it continues to engage with regulators worldwide to expand access to the drug. That approval already rests on the growth-slowing effect GATHER2 measured, so the disclosure functions as a confirmation of a previously established result rather than the introduction of a new one. The trial's registry record shows a completed status since October 2023, with results first posted in December 2023, well before this July 2026 disclosure. Astellas+1

Trial history and stability

GATHER2 raised its enrollment target from 400 to 448 patients in July 2021 and moved its primary completion date twice, from June 2022 to July 2022 and then to July 25, 2022, before completing. Those adjustments predate the current disclosure by roughly four years and reflect ordinary registry housekeeping around a trial that ultimately finished enrollment at target and reported results on schedule relative to its own completion date. NCT04435366

The competitive field

Avacincaptad pegol is the only Phase 3 complement C5 inhibitor to complete testing in geographic atrophy secondary to AMD; no other industry trial has reached Phase 3 for that target-indication pairing. The nearest same-mechanism competitor, Regeneron's pozelimab-cemdisiran combination, is still recruiting in a Phase 3 geographic atrophy trial with a primary completion date in late 2027, while other complement C5 programs from Alexion and Hoffmann-La Roche run in unrelated conditions such as myasthenia gravis and paroxysmal nocturnal hemoglobinuria. Within geographic atrophy itself, mechanistically distinct programs from Belite Bio, Annexon, and Genentech are also active, underscoring that the field has moved past a single validated mechanism even as avacincaptad pegol remains the only complement C5 asset to reach approval there.

This analysis was produced using AI-assisted reporting systems, AppliedXL data, and official public records. These systems undergo editorial review, quality checks, and regular audits by human experts. Errors may still occur, as with any automated system. Always consult the linked primary sources. Read our AI Editorial Policy.